PMG 1015
Alternative Names: PMG-1015Latest Information Update: 16 Sep 2026
At a glance
- Originator Pulmongene
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action MDK protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 20 May 2026 Pharmacodynamics data from a preclinical study in Fibrosis presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
- 20 May 2026 Adverse event and immunogenicity data from phase I trial in Idiopathic pulmonary fibrosis presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
- 27 Sep 2025 Efficacy, adverse events and pharmacokinetics data from a phase Ib trial in Idiopathic pulmonary fibrosis presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)